Investor Presentation
Commercialisation Strategy
US Clinical Trial Partners
•
•
•
4DMedical has existing partnerships with some of the largest and most prestigious hospitals in the US
Existing eight clinical trial partners represent approximately 1% of US hospitals beds, and 1% of the US market revenue
opportunity
Core focus is to continue commercialisation in these hospitals delivering key opinion leader (KOL) support and immediate
revenue opportunities
KOLs have a strong understanding of the benefits of the technology, with XV Technology platform already in use
•
The scale of these initial hospitals presents significant revenue potential in the immediate term
Clinical Trial Partner Name Top 10 Rank
Pre-FDA
revenue
City
Patient Beds
1
Est. Respiratory Potential Revenue Opportunity²
Diagnostics p.a.
(US$m, p.a.)
Cleveland Clinic
4
Y
Cleveland
1,283
119,319 $
20.9
UAB Hospital
Birmingham
1,201
111,693 $
19.5
Vanderbilt University Hospital
Massachusetts General Hospital
Nashville
1,033
96,069 $
16.8
2
Boston
1,011
94,023 $
16.5
The Johns Hopkins Hospital
Duke University Hospital
Cedars-Sinai Health System
Temple University Hospital
3
Baltimore
1,007
93,651 $
16.4
Durham
972
90,396 $
15.8
8
Y
Los Angeles
880
81,840 $
14.3
Philadelphia
732
68,076 $
11.9
8,119
755,067 $
132.1
1: Estimated by approximate annual diagnostic / patient bed ratio of Cleveland Clinic
2: Estimated respiratory diagnostic tests per annum, charged at US$175/test
Pg 28 Investor presentation
4DMedical™
FORMERLY 4DView entire presentation